Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirolimus + sirolimus-generated donor Th2 cells
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This experimental cellular immunotherapy, developed by the National Cancer Institute (NCI), combines the mTOR inhibitor sirolimus (rapamycin) with sirolimus-generated donor Th2 cells (T-Rapa) for the treatment of metastatic renal cell carcinoma. The therapeutic approach involves a low-intensity allogeneic hematopoietic stem cell transplant (HSCT) protocol using a conditioning regimen of pentostatin and cyclophosphamide. Donor Th2 cells are specifically cultured ex vivo in the presence of sirolimus to render them resistant to the drug's immunosuppressive effects. These T-Rapa cells are then administered as multiple donor lymphocyte infusions (DLI) post-transplant. The strategy aims to induce a potent graft-versus-tumor (GVT) effect while concurrent high-dose sirolimus administration serves to prevent graft-versus-host disease (GVHD) without inhibiting the infused, resistant Th2 cells.
- Other names
- rapamycin + Th2 cellssirolimus-resistant allogeneic T cellssirolimus-generated donor Th2 cells
02
Targets
Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on sirolimus + sirolimus-generated donor Th2 cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirolimus + sirolimus-generated donor Th2 cells.